Table 1

Summary of pediatric CML patients with the T315I mutation treated with ponatinib.

Gender	Age (yr)	Disease status at start of ponatinib	KD mutations	Initial ponatinib dose (/day)	Ponatinib treatment duration (m)	Response to ponatinib	Reference
M	10	Disease progression	T315I	45 mg (25 mg/m²)	66	UD	[2, 6]
M	16	Blast phase	T315I E225K	30 mg (19 mg/m²)	3	MR⁴^a)	[6]
M	14.4	Blast phase	T315I E255K		2.5	None	[7]
M	9.3	Blast phase	T315I		1.5	MR⁴	[7]
M	10.8	Blast phase	T315I		5	MMR	[7]
M	8.6	MR^4.5^b)	T315I		1.5	None	[7]

^a)MR⁴ defined as BCR-ABL1 transcript level ≤0.01% according to International Scale. ^b)MR^4.5 defined as BCR-ABL1 transcript level ≤0.0032% according to International Scale.

Abbreviations: KD, kinase domain; MMR, major molecular response; UD, undetectable.

Blood Res 2021;56:342~345 https://doi.org/10.5045/br.2021.2021104